First Hospital of Zhejiang Province
Hangzhou, Zhejiang, 310003, China
NCT Number: NCT03430830
The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Hangzhou, Zhejiang, 310003, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
50mg, Tablet
Other names: ASC16
200mg, Tablet
Other names: ASC16
Time frame: 27 days
Pharmacokinetics (blood draws, pre- and post-dose)
Time frame: 27 days
Pharmacokinetics (blood draws, pre- and post-dose)
Ascletis Pharmaceuticals Co., Ltd.
Industry
A Randomized, Open, Three-dose (100 mg, 200 mg and 300 mg) Duplicate Bifunctional Crossover and Fixed 200mg Continuous Dose Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01010646
Blood-Borne Infections, Chronic Disease
Lyon, France
View Trial DetailsNCT01226446
Blood-Borne Infections, Chronic Disease
Paris, France
View Trial DetailsNCT00200343
Blood-Borne Infections, Chronic Disease
Hongo, Bunkyo-ku, Tokyo, Japan
View Trial DetailsNCT01466192
Blood-Borne Infections, Chronic Disease
Minato-ku, Tokyo, Japan
View Trial Details